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Abstract
Background: The advent of Systems Biology has been accompanied by the blooming of pathway databases.
Currently pathways are defined generically with respect to the organ or cell type where a reaction takes place. The
cell type specificity of the reactions is the foundation of immunological research, and capturing this specificity is of
paramount importance when using pathway-based analyses to decipher complex immunological datasets. Here,
we present DC-ATLAS, a novel and versatile resource for the interpretation of high-throughput data generated
perturbing the signaling network of dendritic cells (DCs).
Results: Pathways are annotated using a novel data model, the Biological Connection Markup Language (BCML), a
SBGN-compliant data format developed to store the large amount of information collected. The application of DC-
ATLAS to pathway-based analysis of the transcriptional program of DCs stimulated with agonists of the toll-like
receptor family allows an integrated description of the flow of information from the cellular sensors to the
functional outcome, capturing the temporal series of activation events by grouping sets of reactions that occur at
different time points in well-defined functional modules.
Conclusions: The initiative significantly improves our understanding of DC biology and regulatory networks.
Developing a systems biology approach for immune system holds the promise of translating knowledge on the
immune system into more successful immunotherapy strategies.
Background
Dendritic cells (DCs) orchestrate a repertoire of immune
responses that endow resistance to infections and toler-
ance to self. DC plasticity has a prominent role in elicit-
ing the proper immune response. Different DC subsets
display different receptors and surface molecules and
express different sets of cytokines/chemokines, all of
which lead to distinct immunological outcomes. Among
the receptors are the innate pattern recognition
receptors (PRRs) that mediate the initial sensing of an
infection. These include Toll-like receptors (TLRs), RIG-
I-like receptors (RLRs), NOD-like receptors (NLRs), and
C-type lectin receptors (CLRs) [1]. TLRs recognize con-
served structures of microbes and are localized on the
cell surface (TLR1, TLR2, TLR4, TLR5 and TLR6) to
recognize bacterial and fungal cell wall components or
in intracellular membranes such as endosomes or pha-
gosomes (TLR3, TLR7, TLR8 and TLR9) where they
recognize viral or microbial nucleic acids [1]. Thus, dif-
ferent TLRs are amenable to targeting by different types
of agents [2].
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Because of their essential role in the initiation of an
adaptive immune response, DCs are an attractive target
for therapeutic manipulation of the immune system [3].
In fact, DC physiology is one of the research areas
where basic knowledge has been more readily translated
into clinical applications. DC-based vaccines have been
rapidly transferred from the laboratory to the clinic.
However, it is evident that, after more than ten years of
worldwide experience with DC vaccination, the thera-
peutic potential of these cells has not yet been entirely
exploited [4]. We thus need to improve our understand-
ing of the complex biology of these cells [5] that operate
at the crossroad of innate and adaptive immunity. The
complexity and heterogeneity of the DC system how-
ever, may require a shift from reductionism to more
holistic systems biology approaches. We expect that
more detailed insight in the signaling pathways that
operate in DCs will open new perspectives for a better
exploitation of their therapeutic potential.
Immune systems biology is defined as the comprehen-
sive and quantitative study of interactions between hosts
and microbes over time, leading to the generation of
models describing their dynamic behavior of immune
cells and pathogens.
Many studies investigated immune cell since these
cells are particularly suited to functional genomics ana-
lyses because their responses to specific stimuli in a
controlled environment can be clearly categorized.
Innate responses against pathogens however cannot be
considered as a set of discrete signaling pathways acti-
vated by a pathogen binding to a receptor; but rather
such responses are composed of many interconnected
pathways depending on multiple factors.
Important initiatives based on systems biology are
arising to collect high throughput data and to develop
sophisticated bioinformatic methods to compare and
analyze these data. In this respect, the Immunological
Genome Project initiative [6] represents the first tran-
scriptomic project to apply a truly systems-level
approach to the analysis of immune cell populations.
Current publicly available pathway databases provide
generic rather than thematic or cell-type specific path-
ways. Nevertheless, certain initiatives are proposing the
cellular specificity of certain reactions. In recent stu-
dies [7] a comprehensive map of macrophage molecu-
lar interactions was created, including ligands such as
PAMPs and interleukins as input signals, and the
release of cytokines and lipids as output signals.
Recently a macrophage specific pathways database
valuable for computational modeling and for the inter-
pretation of functional genomics data has been pub-
lished [8]. At the time of writing, initiatives aiming at
a better description of the signaling networks of DCs
are underway [9].
Here we describe DC-ATLAS, a collection of pathways
specifically curated in DC, that can be exploited, using
pathway analysis based approach, in deciphering the
complex network of interactions occurring in DCs upon
activation. The pathways are available at http://www.
dc-atlas.net and they cover a plethora of cell surface
receptors (eg. TLRs, CLRs, NLRs) and DC-relevant pro-
cesses (e.g antigen presentation, migration). To illustrate
the potential of this new resource, we have selected as
paradigmatic the set of TLRs pathways. We describe
how they were curated and show the advantages of our
approach through their validation both “in silico” and
“in vitro”.
The database contains both human and mice data and
the modular structure of DC-ATLAS led to unravel of
the major differences between these two systems. The
knowledge provided by DC-ATLAS permits the conver-
sion of genomic research into accurate and robust biolo-
gical hypotheses by generating signatures that serve as
valuable tools to understand DC physiology and contri-
bute to the design of new strategies in immunotherapy.
Results
Dendritic cells specific pathways in DC-ATLAS
DC-ATLAS is one of the first immunological and bioin-
formatics integrated project which complies with the
Systems Biology Graphical Notation (SBGN) [10]. It is
composed of a database holding signal transduction
pathways extensively curated specifically for DCs.
Every specific gene and reaction were annotated pro-
viding information on the organism, the organism part,
the cell type and the experimental details in which the
evidence has been obtained. The community of curators
within DC-ATLAS manually annotated the pathways
providing also the most updated reference available in
existing databases and literature, as well as generating
experimental proofs in their own laboratories where
these were lacking. The curation procedure itself is
described in more detail in Additional file 1.
Development of a specific data format for DC-ATLAS
To ensure that the results of the curation process would
also be fully used for representation and data analysis, a
DC specific data format, the Biological Connection
Markup Language (BCML), was developed to represent
pathways according to the specification proposed by the
Systems Biology Graphical Notation (SBGN)[10]. BCML
provides a machine-readable representation of the path-
ways, which can be used for description, manipulation,
analysis and graphical representation. BCML is a format
developed using XML and defines the complete Process
Description (PD) specification from SBGN, including
not only the definition of the elements, but also the
rules and constraints needed to assemble a network.
Cavalieri et al. Immunome Research 2010, 6:10
http://www.immunome-research.com/content/6/1/10
Page 2 of 12
In addition to a full implementation of the PD specifi-
cation, BCML provides a series of optional features. First
of all, BCML can include additional information on the
entities that compose the network: each entity can be
described by a series of species specific database identi-
fiers, e.g. Entrez Gene or Uniprot accession numbers.
Furthermore, each entity or reaction can have a set of
facts or “Findings” associated. “Findings” are collections
of biological information that are relevant to that entity
or reaction. The current specification includes support
for organism, organism part (tissue), cell type, the specific
biological environment in which the evidence was pro-
ven, and the type of the experiment used to gather evi-
dence. To reduce ambiguity and promote consistency
among different “findings”, the schema enforces a con-
trolled vocabulary built from current medical ontologies.
The specification of BCML is accompanied by a series
of programs (BCML software suite) that enable the use
and manipulation of the format both for the bioinforma-
tician and the biologist. First of all, the software suite
permits validation of pathways described using BCML,
to ensure consistency and the proper enforcement of
the SBGN rules. Secondly, the software can create a
fully SBGN compliant graphical representations by
transforming the BCML XML into other formats
(GraphML) which can be then saved as images with
third-party software.
The format also permits filtering of the pathway data
creating a new network containing only elements with
user-defined characteristics, allowing the production of
tailored made pathways, allowing individualized analyses.
The tools in the BCML software suite allow specific “fil-
tering” of the pathway, taking advantage of all the infor-
mation stored. For example, nodes and edges can be
selected for a specific cell type or organism, permitting
the construction of customized network maps to repre-
sent specific biological contexts. When a filter is applied
to the pathway, elements are marked as “included”,
“excluded”, or “affected”. An element of the pathway is
included or excluded in the resulting map if it matches
with the selected filter criteria or not. The “affected”
state is used to indicate elements that may not be pre-
sent depending on the filtering; for example. in a speci-
fic cell type a complex may not form if one or more of
its proteins are not present. Filtering may be used to
assist data analysis and interpretation and might point
to gaps in current knowledge.
The BCML format can incorporate any kind of experi-
mental measurements that can be matched to the iden-
tifiers of an element. This allows modification of the
BCML map, facilitating incorporation of high-through-
put data coming from transcriptomic or proteomic
experiments. The outcome will be visualized in different
color on the graphical map.
Finally, BCML allows transformation of the pathways
into different data formats, which may be needed for
further analysis. Tools provided within the suite allow
the generation of identifier (gene) lists from a BCML
file, enabling their use with analysis tools such as Gene
Set Enrichment Analysis (GSEA), Fisher’s Exact Test.
Additionally, the format can be converted to a form
amenable for impact analysis through the SPIA R pack-
age. This conversion can take into account the filtering
applied to the elements of the pathway, to carry out
individualized analyses.
A detailed description of BCML format is available as
Additional file 2.
TLR pathway curation and modular structure in DC-ATLAS
At present, the human TLR pathway set in DC-ATLAS
is a network organized in an ensemble of 8 pathways
(TLR1-2, TLR2-6, TLR3, TLR4, TLR5, TLR7, TLR8 and
TLR9), subdivided in 10 sensing modules, 32 signal
transduction modules and 30 outcome modules. In con-
trast to what is present in existing databases, TLR7 and
TLR8 were curated separately. Although their genes lie
in close proximity on chromosome X and are highly
homologous, recent evidences suggest they have distinct
roles in DC mediated immune response [11-13]. For
example, despite the fact that both TLRs bind the same
ligand and largely overlap in their signaling, stimulated
TLR7 activates transcription factor IRF7 [14] while IRF1
[15] is only an effector of TLR8 mediated signaling.
Expert-guided, manual curation of the pathways has
been a crucial part of the DC-ATLAS initiative, leading
to a substantial “reshaping” of the existing pathways. For
example, curation of TLR3 pathway led to the validation
of only about 50% of the genes included in the list ori-
ginally retrieved from public databases (Figure 1A and
1B). Furthermore, a number of genes previously not
annotated as belonging to the TLR3 pathway in publicly
available databases were found to participate to the sig-
naling cascade in DCs. Among them, especially the
number of target genes has been substantially extended,
including the cytokines IL-10 [16-19], IL-1a [17], the
chemokines CCL3 [17] and the CCR7 chemokine recep-
tor [20], the co-stimulatory molecule CD83 [16,20], the
transcription factor STAT4 [21] and the enzyme INDO
[19,22].
Another example demonstrating the importance of
DC-ATLAS curation is exemplified by the fact that in
the sensing module of TLR9 we found a new element,
UNC93B1, whose involvement in signaling was demon-
strated already in 2007 [23]. All the other improvements
of DC-ATLAS with respect to existing pathways fall
mainly in the signal transduction and outcome modules.
A summary of all the new genes and/or connections,
not previously annotated in TLR pathways, and present
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in DC-ATLAS is presented in Table 1. Since the field is
rapidly evolving, when new evidence appears demonstrat-
ing that new or so far excluded interactions are operating
in DCs, DC-ATLAS will be updated accordingly.
To facilitate meaningful analysis of “omics” data, the
pathways in DC-ATLAS are organized in a modular
structure. Every signaling cascade downstream a specific
receptor was divided into 3 types of modules in which
the very last component of one module is also the first
component of the subsequent module. The first type of
module is the receptor and sensing module and com-
prises component(s) of the pathway directly interacting
with the stimulus. The second transduction module,
encompasses all components transducing the incoming
signal from the sensing module downstream to the
nucleus. This module generally starts with a molecule
Figure 1 Comparison of the DC-ATLAS Toll Like Receptor (TLR) 3 pathway with other pathway databases. (A) Representation of the
KEGG Toll-like receptor (TLR) pathway. The TLR3 signal is highlighted in red. (B) Representation of the KEGG TLR3 pathway, displaying only the
reactions proven in human DCs. The curation led to the validation of about 50% of the genes previously belonging to public TLR3 signaling.
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interacting with the receptor and ends with a transcrip-
tion factor. The third and final module is the outcome
module: it describes the end result of the signaling pro-
cess. This last module begins with a transcription factor
and includes target genes whose expression is altered
after activation of the receptor. Complex cell functions,
such as apoptosis, migration and differentiation are also
described as outcomes.
According to the previous module definition, the path-
ways in DC-ATLAS may contain more than one of each
type of modules. As an example, Figure 2 shows the modu-
lar structure of the TLR3 pathway curated for DC-ATLAS.
In this pathway, one receptor/sensing module and three
transduction modules leading to the activation of three cri-
tical transcription factors, IRF3, NF-kB and AP-1 have
been identified.
The modules, as we defined them, have been subse-
quently tested using gene expression data as described
in the following paragraphs. It should be emphasized
that the transduction modules are not independent but
are highly interconnected and partially overlapping.
Furthermore, a given outcome may result from activa-
tion of more than one transduction module.
The data format we used to describe the pathway
allowed us to depict interactions in the cellular organelles
where they occur as well as to specifically mark genes
Table 1 DC-ATLAS curation results: number and names of new genes present in TLR pathways of DC
TLR signaling
pathways Cascade
Genes in
revised
pathway
New genes in
revised pathway
Names of new genes or chemicals previously absent from the DCs pathway
(Entrez Gene ID)
TLR1/TLR2 72 21 Transduction modules: SOCS1 (8651), BTK (695), PPARG (5468).
Outcomes: CXCL2 (2920), IL2 (3558), MAP3K8 (1326), MHC (HLA-E (3133), HLA-DMB
(3109), HLA-DOA (3111), HLA-DPA1 (3113), HLA-DPB1 (3115), HLA-DQA1 (3117), HLA-
DQB1 (3119), HLA-DRA (3122), HLA-DRB1 (3123), HLA-DRB3 (3125), HLA-DRB4 (3126),
HLA-DRB5 (3127)), CD86 (942), CCL19 (6363), CCL2 (6347).
TLR2/TLR6 78 26 Transduction modules: SOCS1 (8651), BTK (695), PPARG(5468), PRKCA (5578)
Outcomes: CXCL2 (2920), IL2 (3558), MAP3K8 (1326), MHC (HLA-E (3133), HLA-DMB
(3109), HLA-DOA (3111), HLA-DPA1 (3113), HLA-DPB1 (3115), HLA-DQA1 (3117), HLA-
DQB1 (3119), HLA-DRA (3122), HLA-DRB1 (3123), HLA-DRB3 (3125), HLA-DRB4 (3126),
HLA-DRB5 (3127)), CD86 (942), CCL19 (6363), CCL2 (6347), IL10 (3586), CD80 (941),
CD40 (958), CCR7 (1236).
TLR3 66 23 Transduction modules: PRKCA (5578), PRKCB1(5579), CREBBP (1387), SRC (6714),
AKT1 (207).
Outcomes: IL10 (3586), IL29 (282618), IL28A(282616), IL28B (282617), IL1A (3552),
CCL3 (6348), CCR7 (1236), CD274 (29126), STAT4 (6775), SOCS1 (8651), INDO (3620),
ICAM1 (3383), CD83 (9308), MHC(HLA-DRB5 (3127), HLA-DRB4 (3126), HLA-DRB3
(3125), HLA-DRB1 (3123), HLA-DRA (3122)).
TLR4 100 37 Transduction modules: PI(4,5)P2, IRAK2 (3656), IRAK3 (11213), MAP3K7IP3
(257397), The protein family dynamin (DNM3 (26052), DNM2 (1785), DNM1 (1759)),
RIPK3 (11035), TNKS (8658), AZI2 (64343), TBKBP1 (9755).
Outcomes: IL1A (3552), IL10 (3586), IL12A (3592), IL12B (3593), IL15 (3600), IL23A
(51561), LTA (4049), CCL19 (6363), TNFSF10 (8743), IRF1 (3659), IRF3 (3661), IRF5
(3663), IRF7 (3665), IRF9 (10379), CXCL10 (3627), MHC (HLA-E (3133), HLA-DMB (3109),
HLA-DOA (3111), HLA-DPA1 (3113), HLA-DPB1 (3115), HLA-DQA1 (3117), HLA-DQB1
(3119), HLA-DRA (3122), HLA-DRB1 (3123), HLA-DRB3 (3125), HLA-DRB4 (3126), HLA-
DRB5 (3127)).
TLR5 52 25 Transduction modules: The protein family PI3K (PIK3R2 (5296), PIK3CG (5294),
PIK3CD (5293), PIK3CB (5291), PIK3CA (5290), PIK3C3 (5289), PIK3C2G (5288), PIK3C2B
(5287), PIK3C2A (5286), PIK3R1 (5295), PIK3R5 (23533), PIK3R6 (146850), PIK3R4 (30849),
PIK3R1OS (404543), PIK3R3 (8503)), PRKD1 (5587), AKT1 (207).
Outcomes: CXCL2 (2920), IL18 (3606), CCL20 (6364), IL10 (3586), IL12A (3592), IL12B
(3593), IL18 (3606), CCL2 (6347).
TLR7 56 7 Transduction modules: MEF2C (4208), PIK3CA (5290), PIK3CB (5291), PIK3CG (5294),
IRF4 (3662).
Outcomes: IL12A (3592), IL12B (3593).
TLR8 52 5 Transduction modules: MEF2C (4208), IRF1 (3659).
Outcomes: IL12A (3592), IL12B (3593), NOS2 (4843).
TLR9 54 21 Sensing module: UNC93B1 (81622).
Transduction modules: PIK3CD (5293).
Outcomes: MHCII (HLA-DMB (3109), HLA-DOA (3111), HLA-DPA1 (3113), HLA-DPB1
(3115), HLA-DQA1 (3117), HLA-DQB1 (3119), HLA-DRA (3122), HLA-DRB1 (3123), HLA-
DRB3 (3125), HLA-DRB4 (3126), HLA-DRB5 (3127)), CD80 (941), CD83 (9308), CD86(942),
CD40(958), CCL3 (6348), CXCL10 (3627), ICAM1(3383), CCR7 (1236).
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and interactions according to the biological system (e.g.,
cell type and species) where they took place. Thus, we
were able to create a map of the TLR3 pathway for exam-
ple clearly showing which genes and interactions were
described in DCs and which were not (Figure 3, Addi-
tional file 3 Figure S1 and Additional file 4 Figure S2).
Overall, these results provide strong support for the
importance of curating a pathway with the final aim of
defining all interactions and nodes occurring in a speci-
fic species, cell type and compartment.
DC-ATLAS is a powerful tool to dissect TLR specific
contributions and to analyze time course related
responses
To address the importance of the modular structure of
the DC-ATLAS and its statistical approach in dissecting
the contribution of TLRs, we performed a time-course
transcriptional analysis of moDCs stimulated with LPS
and risiquimod (R848) that respectively activate TLR4
and TLR7/8. We calculated pathway signatures for each
of these datasets and subsequently clustered resulting
pathways (see Methods).
By clustering pathway signatures using publically avail-
able TLR pathways, it proved virtually impossible to
obtain information of individual potentially affected
elements within the TLR pathway, despite clear up-
regulation at the pathway level. Instead, clustering of
DC-ATLAS based results readily showed a separation of
different stimulatory conditions (Figure 4A). The total
matrix used for clustering is available as Additional file 5.
Figure 2 SBGN representation of the DC-ATLAS human TLR3 signaling pathway. The different modules are represented: The Receptor/
Sensing module (R/S, in yellow), the different Transduction modules (T1, light grey; T2, pink; T3, light blue) and the Outcome modules (O1, O2,
O3). The outcomes modules are colored in the same way of the transduction module by which they derived. TRIF is the key element shared by
each transduction module. The outcome module in grey represents the genes which expression is proven in human DCs but the transcription
factor that regulated their expression is not clearly identified.
Figure 3 Presence or absence of specific Toll-like receptor
(TLR) 3 pathway elements in different cell types according to
the currently available knowledge. (A) Section of TLR3 pathway
described in DCs; (B) Section described in macrophages. Grey
elements are members of the pathway whose presence has not
been demonstrated in the specific cell type (DCs and macrophages,
respectively). Blue elements and lines indicate reactions and entities
that depend on absent (grey) members and thus may not occur.
The complete pathway representations are available as Additional
file 3 Figure Sl and Additional file 4 Figure S2.
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As we expected both the TLR7/8 and TLR4 modules
were affected upon specific stimulation, with R848 and
LPS respectively [24]. At early time points, analysis
allowed appreciation of activation of specific signal
transduction modules while at later time points, out-
come modules were clearly activated and sensing mod-
ules were down-regulated or not affected, indicating a
general feedback regulation in fully matured DCs. At
this stage, DCs have committed to their fate and
decided how to respond to a specific stimulus making
some of its sensing receptors redundant. Despite the
overlap between signaling from both receptors, the
cluster analysis indicated how DCs stimulated for 6
hours with R848 behave similarly to cells stimulated for
3 hours with LPS, underlining a slower activation of the
signaling through TLR7/8, perhaps due to their intracel-
lular localization in the endosome. At 24 hours, when
the DC maturation process is completed, the profiles of
the pathway signatures are more similar between the
two stimuli.
Also in time course experiments, the modular structure
of DC-ATLAS allows to appreciate time-dependent
changes in expression providing a more informative analy-
sis. The TLR4-sensing module is repressed at 3 hours of
Figure 4 Pathway analysis on microarray data on DCs stimulated with R848 and LPS using DC-ATLAS pathways. (A) Section of
clustering of PEF and score using Euclidean distance using support trees on DCs stimulated with R848 and LPS for different periods of time: 3,
6, 12 and 24 hours. Colored spots indicate significant up- (red) or down- (green) regulation. The colors of the dendrogram indicate the
percentages of the tree support (significance), from 50% (pink) to 100% (black). The pathways are named as name of receptor_module_adaptor-
TF involved. “s”, “t” and “o” indicated sensing, transduction and outcome module, respectively. The total matrix used for clustering is available as
Additional file 5. (B) Interpolation of DEGs of DCs in response to 3 hours LPS stimulation, the specific agonist of TLR4 signaling, with the gene
lists representative of elements participating in TLR7/TLR8 pathways and representative of elements composing TLR4 pathway (in the Venn
diagram indicated as TLR7, TLR8 and TLR4, respectively). (C) SBGN representation of the TLR4 pathway highlighting gene regulation upon 3
hours-stimulation with LPS. Red indicates up-regulation while green signifies down-regulation. (D) SBGN representation of the TLR4 pathway
highlighting gene regulation at 6 hours. The full figures are available as Additional file 6 Figure S3 and Additional file 7 Figure S4, respectively.
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LPS stimulation. After 12 hours of stimulation, the MyD88
dependent signaling module is less abundant when com-
pared to MyD88 independent transduction modules dur-
ing the earliest time points. As can be seen in Figure 4A,
after 24 hours of LPS stimulation, the outcome modules
activated by AP-1 become repressed. Similarly, upon R848
stimulation, the sensing module is over-represented at
early time points and switched-off later on. After 24 hours,
several parts of the signal transduction module are
repressed as well as the outcome module indicating a
commitment of the cells or a feedback regulation.
Together, these observations nicely demonstrate that,
using DC-ATLAS, we can follow the signal, as a temporal
series of discrete events across all the modules, from sen-
sing to outcome trough the transduction part.
As can be seen from the analysis, in addition to a
single TLR specific pathway, a number of other TLR
pathways can be affected by the stimuli used. This is
because several of the TLR pathways, such as the TLR4
and TLR7/8 pathways, share some elements, although
this does not necessarily mean that their engagement
leads to identical outcome. When analyzing the LPS
dataset at 3 hours, 135 genes were found to be differen-
tially expressed within the DC-ATLAS pathways and
47 of them belonged to the TLR4 signaling pathway
(Figure 4B). Among these, 24 were shared with TLR7/8
pathways, while 23 elements were assigned specific for
TLR4 (Figure 4B).
Given the modular structure and DC specific annota-
tions of DC-ATLAS we can also evaluate individual ele-
ments involved in TLR specific signaling. For example,
we mapped differentially expressed genes upon 3 hours-
LPS stimulation from our data set to the TLR4 pathway
(Figure 4C and Additional file 6 Figure S3). Using this
map and the output of the pathway analysis, it becomes
now possible to appreciate the entire flow of the signal
starting from the receptor till the final activation of the
transcription of specific genes inside the nucleus. It is
well established that TLR4 engagement can result in dif-
ferent signaling, dependent on the adaptors recruited
[25,26]. The signal either starts from MyD88 and the
MyD88-like adapter (TIRAP), or from the TIR-domain-
containing adapter-inducing interferon-beta (TRIF, also
shared by TLR3) and the TRIF-related adapter molecule
(TRAM). We observed that this is highly time depen-
dent as the signal trough TRAM at 3 hours was still
down-regulated (Figure 4C) and became up-regulated at
6 hours after stimulation (Figure 4D and Additional file
7 Figure S4).
These results thus illustrate that the modular structure
of DC-ATLAS allows a better and more detailed under-
standing of TLR mediated signaling in time course
experiments.
DC-ATLAS can discriminate between species-specific
pathways
Currently, studies on mouse DCs outnumber those on
human cells; however, comparisons between mouse and
human models have been somewhat biased due to biolo-
gical differences between both species [27] as well as dif-
ferences in the origin of the material used to study DCs,
e.g. bone marrow derived mouse DCs (BMDC) versus
monocyte derived human DCs (moDCs). The species-
specific curation of the DC-ATLAS pathways allowed us
to highlight the differences between mouse and human
model DC signaling in response to similar stimuli (Figure
5). When we perform a pathway and cluster analysis on
publically available human moDC- (GSE2706, GSE4984)
and mouse BMDC- (GSE15087) datasets, we could
clearly identify a different profile from the mouse data
when compared with the human data, even though they
were both stimulated with LPS (Figure 5), although we
should take into account they were derived from different
progenitors. The total matrix used for clustering is
available as Additional file 8.
Discussion
An immune response forms a complex biological system
with many possible inputs, influences and outcomes, in
which DCs play a critical role. The relationship among
the different immune cells subsets and model systems
are currently under active debate, highlighting the
importance of annotating signaling pathways in respect
of both the cell type and the species in which the path-
way was found.
Zanoni et al. reviewed the divergent responses of DCs
and macrophages upon LPS [28], and despite the evolu-
tionary conserved mechanisms between the human and
murine immune system, an increasing number of studies
Figure 5 Pathway analysis on microarray data on human or
mouse DCs stimulated with TLR ligands. Dendogram of PEF
cluster and score using Euclidean distance using support trees on
human moDC or mouse bone marrow derived DCs (BMDCs)
stimulated with LPS. The numbers next to the tree indicate the
support (significance): higher values mean higher significance. The
total matrix used for clustering is available as Additional file 8.
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demonstrate that several cell-specific differences in sig-
nal transduction exist [29].
Studying DCs using an immune systems biology
approach facilitated by DC-ATLAS, holds promise to
dissect the integrated signals from these cells. This
allows us to build models of the complex process of DC
regulation and generate predictions and hypotheses
about DC function under physiological and pathological
conditions. However, the road forward is not without
obstacles. There is a strong need of a greater coverage
of network data, improved accuracy and standardization
of annotation. The extraction of signal transduction
maps from gene expression data requires well-structured
pathway definitions. Similarly to the recently published
DC pathway map [9], DC ATLAS is an integrated pro-
ject incorporating both immunology and bioinformatics,
focused on signaling pathways in DCs. Yet, with respect
to other existing resources, DC-ATLAS denotes major
advancements. It describes the reactions based on con-
sensus reached by a large number of leading European
immunological scientists with expertise in DCs. The
pathways represent a valuable tool to emphasize estab-
lished facts as well as to highlight limitations in our
knowledge with respect to the hierarchy of events lead-
ing to effective immune responses. DC-ATLAS is the
first SBGN compliant pathway databases implemented
using the novel Biological Connection Markup Language
(BCML). DC-ATLAS integrates a detailed pathway
information with experimental data allowing data analy-
sis in a DC-specific manner. It is the first example of a
modular approach to describe signal transduction path-
ways. Here, sets of reactions that participate in a com-
mon regulatory unit were functionally categorized as
part of what we defined as a “module”. The intercon-
nected modules, which describe the DC-ATLAS path-
ways from receptors to effectors via signal mediators,
overcome a major limitation of the current pathway
structures, in which specific events are masked by a
plethora of generic interactions.
The presented results show how DC-ATLAS allows
temporal dissection of events within the signal, repre-
sented by 3 different modules grouping the sensing/
receptor, the transduction of the signal and outcome
pool. The pathway analysis perturbations, with these
modular pathways, visualize the signal propagation,
keeping track of the flow of information.
As demonstrated by LPS and R848 stimulation of DCs
(Figure 4A), the upregulation of outcome modules often
corresponds to down-regulation of sensing/receptor
modules at later time-points. This reverse regulation of
modules has to be interpreted as the presence of a nega-
tive regulatory feedback loop from the outcome to the
sensing module. This retrograde regulation is well
documented in literature [30]. Sensor proteins undergo
a rapid turnover and the regulation of their abundance
is required to maintain the plasticity of the system. As a
consequence, in TLR mediated signaling the transcrip-
tion of genes encoding receptor proteins appears acti-
vated in the first 1-3 hours following stimulation, and
down-regulated as soon as the cells becomes committed.
Interestingly, key elements of the signal transduction
module remain transcriptionally controlled despite the
fact that propagation of these signals depend on events
such as phosphorylation or protein binding, in agree-
ment with a recent report by Buschow et al. [31].
This type of dissection of the flow of information
described as changes in gene expression is made possible
solely by the use of BCML. It provides a suitable format
to store the information collected and organized by the
curators and to build the modular pathways. Our goal
was to provide a data format that was easily extensible
and manipulable for computational analyses, but at the
same time intuitive and user friendly for both cell biolo-
gist and immunologist communities. BCML satisfies
these needs thanks to its flexibility, which permits its use
in computational analysis and in the conversion to a
SBGN compliant graphical map. The possibility of filter-
ing permits the creation of “customized” networks, better
suited to identify specific biological problems or to high-
light gaps in current knowledge. At this moment, BCML
only covers the SBGN Process Description. In the near
future we will also integrate. the SBGN Entity Relation-
ship and Activity Flow representation. in order to provide
a complete representation of SBGN at the data level.
We developed our own format since neither of the
many existing formats such as KGML, BioPAX [32] or
SBML [33] were suitable: some formats lacked a biologi-
cal graphical representation (SBML), while others were
not SBGN compliant (BioPAX, KGML).
Being SBGN compliant and machine readable, BCML
provides a convenient and precise way to represent bio-
logical pathways, in an intuitive and user friendly format
to both the biologist and the bioinformatician.
Because of the more refined modular description of
pathways in DC-ATLAS, the results of statistical analysis
are much improved with respect to the results one can
obtain from existing pathway databases.
The modular pathway of DC-ATLAS allows more
accurate capture of signaling pathways. In many cases
pathway modules are not specific for just one stimulus.
This overlap is expected given the combinatorial nature
of the module structure and definition that describes
the biological nature of signal transduction in DCs. This
is an important feature, as the decision making process
of DCs often integrates signaling from multiple recep-
tors and temporal integration of multiple sets of stimuli.
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Conclusions
New computational methods such as DC-ATLAS will
contribute to fill in current gaps in the analysis of geno-
mic data. Furthermore, the ability of DC-ATLAS to
identify gaps in our current knowledge will foster future
research within the immune system, and lead to the
design of novel experiments aimed at reconciling inter-
actions and findings documented in human and mouse
DCs. In addition, DC-ATLAS will establish the relation-
ships between pathways operating within DCs and other
cell types of different species.
In conclusion, DC-ATLAS provides a knowledge base
on DC biology with the potential to decipher the com-
plex network of interactions occurring within these cells
in response to activation stimuli. This knowledge allows
the conversion of genomic research into accurate and
robust biological hypotheses. Extracting results from
large expression datasets using DC-ATLAS will enable
us to validate experimentally defined pathways and gen-
erate signatures that will serve as valuable tools in the
design of new strategies for DC-based immunotherapy.
Methods
Pathway curation process
We selected several pathways of interest for immunology,
in particular for DC activation, as TLRs pathways and
curated them. We handled the currently available informa-
tion from the literature and from public available pathway
databases, such as KEGG, Reactome and GenMAPP,
evaluating the quality of the data, as well as experimental
evidence generated in our laboratories to curate/design
the pathways in a cell specific manner. Detailed informa-
tion are available on line as Additional file 1.
Pathway representation
Pathways were drawn following the SBGN Process
Description (PD) 1.1 specification [10]. Following cura-
tion, pathway were represented using the Biological Con-
nection Markup Language (BCML), a machine-readable
data format built on the SBGN specification, including all
the information collected by the curators (Additional
Material: Curation Process). The BCML representation
was then transformed to a graphical map. Detailed infor-
mation are available on line as Additional file 2.
The DC-ATLAS pathways were also represented in
GPML (using an in-house modified version of the Path-
Visio program [34]) and INOH format (http://www.
inoh.org), (http://www.dc-atlas.net).
DCs transcriptional analysis to pure TLR ligands
Peripheral blood mononucleated cells (PBMC) were iso-
lated from buffy coat blood sample from healthy donors
from the Transfusion Unit Erlangen hospital (Erlangen,
Germany) by Ficoll-Hypaque density gradient centrifu-
gation (Biochrom AG). The experimental plan was
approved by the local Ethical Committee, and informed
consent was obtained from all donors. Monocytes were
isolated from low density PBMCs by magnetic enrich-
ment with anti-CD14 beads (Miltenyi Biotec). Cells were
cultured in the presence of granulocyte macrophage col-
ony stimulating factor (GM-CSF, 800 U/ml) and recom-
binant IL-4 (1000 U/ml) for 6 days to allow DC
differentiation [35]. 2 × 106 DCs were cultivated with
LPS (100 ng/ml) or R848 (2,5 μg/ml) or without any sti-
muli. After 3, 6, 12 and 24 hr, cells were collected. RNA
preparation, labeling with Cy5, hybridization on a
Human HT12 array (Illumina), and scanning were per-
formed according to the Illumina reference protocols.
Array pre-processing
Bead-summary data saved from Illumina BeadStudio
was pre-processed in several steps. Firstly, the back-
ground signal was assessed and corrected using the
intensity signal from the control probes present on the
array, then quantile normalization was performed. In
addition to background correction, Illumina probe iden-
tifiers were converted to nucleotide universal IDentifiers
(nuIDs) [36] specific for the nucleotide sequence of each
probe. The computation was performed using the lumi
package [37], written in the R programming language.
Microarray data have been submitted to the Array
Express repository, with the accession number E-
MTAB-448.
Public data sets and data preprocessing
Publicly available data sets were retrieved from the Gene
Expression Omnibus (GEO) database. After retrieving,
they were normalized with the Robust Multi-array Average
(RMA) method [38] in the case of Affymetrix data, and
with quantile normalization for other array platforms. Affy-
metrix data were also re-annotated with the most recent
data available following the procedure by Dai et al. [39].
Preprocessing was performed with the RMAExpress soft-
ware (Affymetrix data; http://rmaexpress.bmbolstad.com)
or with the R programming language (other platforms).
Pathway analysis
Pathway analysis was performed with PathStudio (Bel-
trame et al., unpublished data), over the compendium of
DC-ATLAS TLR pathways. Prior to the analysis, micro-
array raw data were transformed into absolute-scale
values and processed following the procedure outlined
by [40]: firstly, ratios between each treated condition
and the unstimulated controls were calculated. Then, in
an effort to reduce inter donor variability, the mean of
the ratios for all replicates in a specific condition was
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calculated. The resulting ratios were used to perform
pathway analysis using the Fisher’s Exact Test and the
resulting signed p-values were transformed into Pathway
Enrichment Factors (PEFs), applying a scoring metric
rather than the Fisher’s Exact Test transformed p-value
for pathways with less than five elements. PEFs were
clustered using multiscale bootstrap resampling [41]
over 1000 iterations.
Additional material
Additional file 1: Curation process description. The procedure of
curation taken towards the reconstruction and editing of the public
available DC pathways and the de novo curation of pathways not
previously presented in public databases.
Additional file 2: BCML Description. The definition of the Biological
Connection Marked Language and the description of its features.
Additional file 3: Figure S1: SBGN representation of the TLR3
signaling pathway highlighting the reactions that occur only in
dendritic cells. Black elements are entities whose presence has been
demonstrated in dendritic cells (DCs); grey elements indicate entities
whose presence has not been demonstrated in DCs. Blue elements
highlight reactions that depend on non present (grey) elements and
thus may not occur.
Additional file 4: Figure S2: SBGN representation of the TLR3
signaling pathway highlighting the reactions that occur only in
macrophages. Black elements are entities whose presence has been
demonstrated in dendritic cells (DCs); grey elements indicate entities
whose presence has not been demonstrated in DCs. Blue elements
highlight reactions that depend on non present (grey) elements and
thus may not occur.
Additional file 5: Pathways analysis results of LPS vs R848
comparison: input matrix. A matrix of Pathway Enrichment Factors
(PEFs) obtained from the transformation of the signed p-values derived
from the pathway analysis. This matrix can be used for clustering using
multiscale bootstrap resampling or other methods.
Additional file 6: Figure S3: Enriched genes found to be part of
TLR4 signaling upon LPS stimulation superimposed to the SBGN
pathway map. Differentially expressed genes of DCs stimulated for 3
hours with LPS present in the TLR4 signaling superimposed to the
pathway map. Red nodes indicate that the respective genes are up-
regulated, and green nodes indicate down-regulated genes.
Additional file 7: Figure S4: Enriched genes found to be part of
TLR4 signaling upon LPS stimulation superimposed to the SBGN
pathway map. Differentially expressed genes of DCs stimulated for 6
hours with LPS present in the TLR4 signaling superimposed to the
pathway map. Red nodes indicate that the respective genes are up-
regulated, and green nodes indicate down-regulated genes.
Addtional file 8: Pathways analysis results of human vs mouse
comparison: input matrix. A matrix of Pathway Enrichment Factors
(PEFs) obtained from the transformation of the signed p-values derived
from the pathway analysis. This matrix can be used for clustering using
multiscale bootstrap resampling or other methods.
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